Analyst Price Target Update on Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) stock has received a short term price target of $ 12.58 from 3 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $5.08. The higher estimate of target price is $16 , while the lower price target estimate is $7

Many analysts have stated their opinion on the company shares. In a research note released to the investors, JMP Securities maintains its rating on Halozyme Therapeutics (NASDAQ:HALO).The analysts at the brokerage house have a current rating of Market Outperform on the shares. In a recent information released to the investors, JMP Securities lowers the new price target from $22 per share to $20 per share. The rating by the firm was issued on March 9, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CFO of Halozyme Therapeutics Inc, Stelzer Laurie, had purchased 10,000 shares in a transaction dated on August 20, 2015. The transaction was executed at $17.24 per share with total amount equaling $172,400.

Halozyme Therapeutics (NASDAQ:HALO) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.08 points or 0.91% at $8.67 with 1,494,386 shares getting traded. Post opening the session at $8.65, the shares hit an intraday low of $8.62 and an intraday high of $8.92 and the price was in this range throughout the day. The company has a market cap of $1,120 million and the number of outstanding shares have been calculated to be 129,139,743 shares. The 52-week high of Halozyme Therapeutics (NASDAQ:HALO) is $25.25 and the 52-week low is $6.96.

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.